K. Bolsewig, A.A.J.M. van Unnik, E.R. Blujdea, M.C. Gonzales, and N.J. Ashton report no disclosures relevant to the manuscript. D. Aarsland reports receiving research support and/or honoraria from AstraZeneca, H. Lundbeck, Novartis Pharmaceuticals, Biogen, Evonik, Sanofi, Roche, and GE Health and serving as a paid consultant for H. Lundbeck, Eisai, Heptares, and Mentis Cura. H. Zetterberg has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). A. Padovani reports no disclosures relevant to the manuscript. L. Bonanni reported receiving grants from the European Commission and the Italian Ministry of Health outside the submitted work. B. Mollenhauer reports no disclosures relevant to the manuscript. S. Schade received institutional salaries supported by the EU Horizon 2020 research and innovation program under grant agreement no. 863664 and by the Michael J. Fox Foundation for Parkinson's Research under grant agreement no. MJFF-021923. He is supported by a PPMI Early Stage Investigators Funding Program fellowship of the Michael J. Fox Foundation for Parkinson's Research under grant agreement no. MJFF-022656. R. Vandernberghe's institution has a clinical trial agreement (R. Vandenberghe as PI) with AviadoBio, Biogen, Denali, J&J, NovoNordisk, Prevail, Roche, UCB, Wave. R. Vandenberghe's institution has a consultancy agreement (R. Vandenberghe as a consultant) with ACImmune, Novartis, and Roche. K. Poesen and M.G. Kramberger report no disclosures relevant to the manuscript. C. Paquet reports serving as a member of the international advisory boards for Lilly; serving as a consultant for Fujiribio, Alzohis, Neuroimmune, Ads Neuroscience, Roche, AgenT, and Gilead; being involved as an investigator in several clinical trials for Roche, Eisai, Lilly, Biogen, AstraZeneca, Lundbeck, and Neuroimmune; and being a current member of the national boards of Roche, Lilly, and Biogen. O. Bousiges, B. Cretin, and E.A.J. Willemse report no disclosures relevant to the manuscript. C.E. Teunissen has a collaboration contract with ADx Neurosciences, Quanterix, and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Fujirebio, Grifols, Instant Nano Biosensors, Merck, Novo Nordisk, PeopleBio, Roche, Siemens, Toyama, and Vivoryon. She is an editor of Alzheimer Research and Therapy, and serves on editorial boards of Medidact Neurologie/Springer, and Neurology: Neuroimmunology & Neuroinflammation. She had speaker contracts for Roche, Grifols, Novo Nordisk. A.W. Lemstra reports no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.
PubMed
